|Mr. Robert B. Bazemore Jr.||Pres, CEO, Sec. & Director||1,01M||N/A||1968|
|Mr. Paolo Tombesi||Chief Financial Officer||628,41k||N/A||1964|
|Mr. Matthew E. Ros||Exec. VP and Chief Strategy & Bus. Officer||644,06k||N/A||1967|
|Dr. Shefali Agarwal M.D., MPH||Chief Medical Officer||737,27k||N/A||1974|
|Dr. H. Robert Horvitz||Co-Founder & Chairman of the Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Yi Zhang||Scientific Co-Founder & Member of The Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Joseph Beaulieu||Controller, Treasurer & Principal Accounting Officer||N/A||N/A||1981|
|Dr. Jeffery L. Kutok||Chief Scientific Officer||N/A||N/A||1967|
|Jason Fredette||VP of Investor Relations||N/A||N/A||N/A|
|Mr. John F. Weidenbruch||Gen. Counsel||N/A||N/A||1961|
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Epizyme, Inc.s ISS Governance QualityScore, Stand 31. Oktober 2019, lautet 7. Die grundlegenden Scores sind Audit: 1, Vorstand: 6, Shareholderrechte: 7, Kompensation: 7.